Atacand to be divested to Cheplapharm in Europe

RNS Number : 5180V
AstraZeneca PLC
24 July 2018
 

24 July 2018 07:00 BST

 

Atacand to be divested to Cheplapharm in Europe

 

Agreement expands the commercial potential of Atacand in 28 European countries

 

AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine for the treatment of heart failure and hypertension.

 

Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca, said: "This agreement forms part of our strategy of streamlining our portfolio of mature medicines to enable reinvestment in our main therapy areas and bringing new medicines to patients. Cheplapharm's strong European presence will help expand the commercial potential of Atacand."

 

The agreement is expected to complete in the third quarter of 2018. AstraZeneca will continue to manufacture and supply Atacand and Atacand Plus under a supply agreement and will continue to commercialise the medicines in all markets where it still holds the rights.

 

Financial considerations

Cheplapharm will pay AstraZeneca $200 million on completion of the agreement, plus a time-bound payment of $10 million and sales-contingent milestones. The upfront and time-bound payments are expected to be reported in the Company's financial statements in 2018. All income is expected to be reported as Other Operating Income. In 2017, global Product Sales for Atacand and Atacand Plus were $300 million, including $86 million in Europe. The agreement does not impact the Company's financial guidance for FY 2018.

 

About Atacand

Atacand (candesartan cilexetil) is a selective, AT1 subtype angiotensin II receptor antagonist blocker (ARB) that is indicated for the treatment of hypertension and heart failure. Atacand is also available in Europe as a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide (Atacand Plus). Atacand is indicated for the management of hypertension in adults and children/adolescents, as well as heart failure in adults. Atacand Plus is indicated for the management of hypertension when monotherapy is not sufficiently effective. Atacand was developed in collaboration with Takeda. Each company holds the exclusive rights to the product in certain markets. In other markets, Atacand is co-marketed by both parties.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations



Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen

 

 

+44 203 749 5712

Josie Afolabi


+44 203 749 5631

Craig Marks

Finance; Fixed Income; M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

US toll-free


+1 866 381 7277




Adrian Kemp

Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFKQDDPBKKPOB

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings